Literature DB >> 2193025

In the absence of a downstream element, the apolipoprotein E gene is expressed at high levels in kidneys of transgenic mice.

W S Simonet1, N Bucay, S J Lauer, D O Wirak, M E Stevens, K H Weisgraber, R E Pitas, J M Taylor.   

Abstract

Human apolipoprotein (apo) E gene constructs with 30 or 5 kilobases of 5'-flanking and 1.5 kilobases of 3'-flanking regions were used to create transgenic mice. High levels of human apoE mRNA were present in the transgenic kidney, but none was detected in the liver, which is normally the major source of apoE. When a construct with 5 kilobases of 5'- and 23 kilobases of 3'-flanking regions was used, only trace levels of human apoE mRNA were detected in the kidney, whereas high levels were found in the liver. These results indicated that regulatory elements downstream of the human apoE gene interacted with the transcription initiation complex to stimulate gene expression in the liver while suppressing expression in the kidney. In each case, human apoE was secreted into the plasma. The source of human apoE in the transgenic kidney was the epithelial cells lining the proximal tubule and Bowman's capsule.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2193025

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain.

Authors:  S Grehan; E Tse; J M Taylor
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

2.  Transcription factor AP-2 regulates human apolipoprotein E gene expression in astrocytoma cells.

Authors:  M A García; J Vázquez; C Giménez; F Valdivieso; F Zafra
Journal:  J Neurosci       Date:  1996-12-01       Impact factor: 6.167

3.  Neuritin: a gene induced by neural activity and neurotrophins that promotes neuritogenesis.

Authors:  G S Naeve; M Ramakrishnan; R Kramer; D Hevroni; Y Citri; L E Theill
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

4.  Prominent expression of the selenoprotein thioredoxin reductase in the medullary rays of the rat kidney and thioredoxin reductase mRNA variants differing at the 5' untranslated region.

Authors:  A K Rundlöf; M Carlsten; M M Giacobini; E S Arnér
Journal:  Biochem J       Date:  2000-05-01       Impact factor: 3.857

5.  Overexpression of apolipoprotein E in transgenic mice: marked reduction in plasma lipoproteins except high density lipoprotein and resistance against diet-induced hypercholesterolemia.

Authors:  H Shimano; N Yamada; M Katsuki; M Shimada; T Gotoda; K Harada; T Murase; C Fukazawa; F Takaku; Y Yazaki
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

6.  Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice.

Authors:  B J van Vlijmen; A M van den Maagdenberg; M J Gijbels; H van der Boom; H HogenEsch; R R Frants; M H Hofker; L M Havekes
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

7.  Megalin contributes to the early injury of proximal tubule cells during nonselective proteinuria.

Authors:  Yaeko Motoyoshi; Taiji Matsusaka; Akihiko Saito; Ira Pastan; Thomas E Willnow; Shuki Mizutani; Iekuni Ichikawa
Journal:  Kidney Int       Date:  2008-09-03       Impact factor: 10.612

8.  Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences.

Authors:  X C Jiang; L B Agellon; A Walsh; J L Breslow; A Tall
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

Review 9.  Transgenic mouse models of lipoprotein metabolism and atherosclerosis.

Authors:  J L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

10.  Type III hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein E.

Authors:  S Fazio; Y L Lee; Z S Ji; S C Rall
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.